top of page

Softlanding completed!

DIVERSA Technologies and BioCat agreement marks new milestone in internationalization thanks to new service BiointeRNational

  • The cooperation between BioRN and DIVERSA within the framework of EIT Health BRIDGEHEAD program laid the foundation for the expansion considerations of DIVERSA into foreign markets.

  • DIVERSA was founded in 2022 and is specialized in drug delivery nanotechnologies for the development of new therapeutic molecules.

Kick-Off-Meeting DIVERSA and BioCat. from l: Víctor A. Francis,Dr. Sieke Schaepe, and Arantxa Encinas López

Credit: BioRN

  • BioRN expands its engagement in supporting companies tackling new markets by launching its new service division BiointeRNational.

  • The distributor agreement that has now been concluded with BioCat GmbH in Heidelberg, is another important milestone for the young start-up.

DIVERSA has big plans: The Spanish company was founded in 2022 and provides delivery solutions in drug development to overcome biological barriers. Already in 2022, DIVERSA started its expansion offensive on the German-speaking market and since then has been working with BioRN to develop the internationalization strategy as part of the EIT Health BRIDGEHEAD program.

Víctor A. Francis, Business Development Director at DIVERSA did part of his PhD at DKFZ and is convinced that the German-speaking market will offer promising business-opportunities for DIVERSA. The softlanding strategy has been developed and put into practice together with Arantxa Encinas López, Project Manager for internationalization services at BioRN.

The newly established BioRN service BiointeRNational evaluates the technologies offered by mature start-ups and supports those considered to be a good fit for the region and beyond. BiointeRNational includes the identification of Key Opinion leaders and distributors, introduction and support throughout the collaboration, Market introduction (tailor-made workshops about the German healthcare system, reimbursement pathways and regulatory) and Marketing support.

“Our service is personalized, we open doors and accompany these European innovators during their penetration journey in Germany”, explains Arantxa Encinas López.

With its large network of leading healthcare players, world-renowned research centers, biotech companies, service providers and global pharma companies BioRN is the bridge to one of the strongest life science hubs worldwide.

DIVERSA presented itself as member of the BioRN network at the BioRN Annual Conference in October 2022, where it was able to hold numerous discussions with the community and make new high-level contacts. The company now has made another important step on its path of internationalization: The distributor agreement for the DACH region has been signed with BioCat Heidelberg, a company with more than 20 years of experience in marketing innovative products and services for life science research.

“The cooperation will help us to promote our innovative products in the DACH markets and collect feedback from customers by working hand in hand. We are very excited for the potential of this partnership”, says Víctor A. Francis.

“At BioCat we are continuously striving to complement our product portfolio with novel products and technologies. Therefore, we are very excited to partner with DIVERSA and think that their patented novel nanotechnology will improve and accelerate drug delivery and development”, explains Sieke Schaepe, Head of Inside Sales & Product Management at BioCat.

As the demand for drug delivery systems remains strong BioCat is convinced that the arrangement will attract new business.


DIVERSA biotechnology is a spin-off from the Santiago de Compostela Health Research Institute and the Galician Health Service, founded in 2022. DIVERSA reagents are easy to use, promoting fast intracellular delivery, stable in cell culture and with high loading capacity as well as biocompatible and designed for any research lab without experience in pharmaceutical formulation.

More information:

About BioCat

BioCat, located in the Heidelberg Technology Park in close proximity to the German Cancer Research Center, was founded in 2000 to market innovative products and services for life science research. BioCat offers a wide range of high-quality research reagents and instruments as well as cutting-edge technologies in the fields of genomics, proteomics and cell biology fueling science in academia as well as in pharma & biotech industry.

More information:

About BioRN

BioRN is the science and industry innovation cluster in the Rhine-MainNeckar region, one of Germany’s strongest biotech and life-science hubs in Germany. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing, and connecting the regional innovation stakeholders. BioRN has more than 140 institutional members, including the top academic and research institutions, 10 global pharmaceutical companies, a large range of small and medium-sized enterprises bolstering the life science ecosystem as well as local government organizations and interest groups. As a leading life science cluster BioRN is committed to facilitating the framework conditions for start-ups with the aim of attracting global investment and talents to the region. BioRN is also founding partner of BioLabs Heidelberg, a leading shared laboratory space for life science and biotech startups.

Follow us on Twitter (@BioRNCluster) and LinkedIn. (

Press release for download:

Download PDF • 156KB

Media contact:

BioRN Network e.V.

Stephanie Füller

PR Manager


bottom of page